Traitement du mélanome par les inhibiteurs du contrôle immunitaire

Jeremy Lupu; Pierre Hamann; Émilie Routier; Caroline Robert

Traitement du mélanome par les inhibiteurs du contrôle immunitaire

Jeremy Lupu, Pierre Hamann, Émilie Routier, Caroline Robert

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

Résumé

Immunotherapy with checkpoints inhibitors stimulates the anti-tumor response. It has dramatically changed the prognosis of advanced melanoma and other cancers. Anti-PD1, alone or in combination with anti-CTLA4, has demonstrated significantly better response and overall survival rates than chemotherapy. The immuno-mediated toxicity is more frequent and more serious with the combination of anti-PD1 and anti-CTLA4, which also appears as the most effective treatment for metastatic melanoma. Adjuvant anti-PD1 therapy is also effective in preventing recurrence in patients with resected stage III or IV melanoma. Studies are underway to evaluate this treatment in a neo-adjuvant situation and in localized melanomas with high risk of recurrence (stage II) with promising results.

Titre traduit de la contribution	TREATMENT OF MELANOMA WITH IMMUNE CHECKPOINTS INHIBITORS
langue originale	Français
Pages (de - à)	330-334
Nombre de pages	5
journal	Revue du Praticien
Volume	71
Numéro de publication	4
état	Publié - 1 avr. 2021

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{22ecec3936e04d01ae741e0f7f9e6e25,

title = "Traitement du m{\'e}lanome par les inhibiteurs du contr{\^o}le immunitaire",

abstract = "Immunotherapy with checkpoints inhibitors stimulates the anti-tumor response. It has dramatically changed the prognosis of advanced melanoma and other cancers. Anti-PD1, alone or in combination with anti-CTLA4, has demonstrated significantly better response and overall survival rates than chemotherapy. The immuno-mediated toxicity is more frequent and more serious with the combination of anti-PD1 and anti-CTLA4, which also appears as the most effective treatment for metastatic melanoma. Adjuvant anti-PD1 therapy is also effective in preventing recurrence in patients with resected stage III or IV melanoma. Studies are underway to evaluate this treatment in a neo-adjuvant situation and in localized melanomas with high risk of recurrence (stage II) with promising results.",

author = "Jeremy Lupu and Pierre Hamann and {\'E}milie Routier and Caroline Robert",

year = "2021",

month = apr,

day = "1",

language = "Fran{\c c}ais",

volume = "71",

pages = "330--334",

journal = "Revue du Praticien",

issn = "0035-2640",

number = "4",

}

TY - JOUR

T1 - Traitement du mélanome par les inhibiteurs du contrôle immunitaire

AU - Lupu, Jeremy

AU - Hamann, Pierre

AU - Routier, Émilie

AU - Robert, Caroline

PY - 2021/4/1

Y1 - 2021/4/1

N2 - Immunotherapy with checkpoints inhibitors stimulates the anti-tumor response. It has dramatically changed the prognosis of advanced melanoma and other cancers. Anti-PD1, alone or in combination with anti-CTLA4, has demonstrated significantly better response and overall survival rates than chemotherapy. The immuno-mediated toxicity is more frequent and more serious with the combination of anti-PD1 and anti-CTLA4, which also appears as the most effective treatment for metastatic melanoma. Adjuvant anti-PD1 therapy is also effective in preventing recurrence in patients with resected stage III or IV melanoma. Studies are underway to evaluate this treatment in a neo-adjuvant situation and in localized melanomas with high risk of recurrence (stage II) with promising results.

AB - Immunotherapy with checkpoints inhibitors stimulates the anti-tumor response. It has dramatically changed the prognosis of advanced melanoma and other cancers. Anti-PD1, alone or in combination with anti-CTLA4, has demonstrated significantly better response and overall survival rates than chemotherapy. The immuno-mediated toxicity is more frequent and more serious with the combination of anti-PD1 and anti-CTLA4, which also appears as the most effective treatment for metastatic melanoma. Adjuvant anti-PD1 therapy is also effective in preventing recurrence in patients with resected stage III or IV melanoma. Studies are underway to evaluate this treatment in a neo-adjuvant situation and in localized melanomas with high risk of recurrence (stage II) with promising results.

UR - http://www.scopus.com/inward/record.url?scp=85203061385&partnerID=8YFLogxK

M3 - Article

C2 - 34161002

AN - SCOPUS:85203061385

SN - 0035-2640

VL - 71

SP - 330

EP - 334

JO - Revue du Praticien

JF - Revue du Praticien

IS - 4

ER -